Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Nivolumab in Transformed CLL or NHL
NCT03884998Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jul 2019
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in Richter syndrome (RS) and non-Hodgkin lymphoma (NHL), sponsored by City of Hope. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events at 48 weeks. Started Jul 2019; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
Richter syndrome (RS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03884998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03884998.